Welcome to our dedicated page for Evaxion AS SEC filings (Ticker: EVAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Evaxion A/S (EVAX) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, primarily filed as Form 6-K current reports and other registration statements. As a foreign private issuer listed on the Nasdaq Capital Market, Evaxion files under Form 20-F and uses Form 6-K to furnish press releases and key corporate information to investors.
Evaxion’s recent 6-K filings frequently incorporate press releases that describe clinical and preclinical data from its AI-Immunology™ powered vaccine programs, including oncology candidates such as EVX-01 and EVX-04 and infectious disease programs like EVX-V1 and EVX-B2. These filings can give investors additional context on trial design, data readouts, and scientific presentations at major conferences.
Other 6-K reports document capital structure changes, such as amendments to the Articles of Association following share capital increases from investor warrant exercises. These filings outline new share issuances, nominal capital changes and related cash considerations, helping readers understand dilution, equity financing and the evolution of Evaxion’s capital base.
Evaxion also uses 6-Ks to furnish business updates and financial results, including quarterly performance, cash runway commentary, partnership income from out-licensed assets like EVX-B3, and information on capital market activities. In addition, the company’s registration statements on Forms F-1, F-3 and S-8 are referenced in 6-Ks through incorporation by reference language, indicating how new disclosures become part of existing prospectuses.
On Stock Titan, these filings are presented with AI-powered summaries that highlight the main points of each document, from scientific milestones to financing transactions. Users can quickly scan new 6-K submissions, identify filings related to clinical data, capital raises or governance changes, and then dive into the full text for deeper analysis. This page is a central resource for tracking EVAX’s regulatory reporting, capital markets activity and the formal record of its AI-Immunology™ platform and pipeline developments.
Evaxion A/S (NASDAQ: EVAX) filed a Form 6-K on 11 July 2025 to furnish a press release announcing that the Company has finalized an agreement with the European Investment Bank (EIB) to convert existing debt into equity. The press release, provided as Exhibit 99.1, is the only substantive disclosure contained in the filing. No additional terms, financial amounts, or timing details are included in the 6-K.
Evaxion (NASDAQ: EVAX) filed a Form 6-K furnishing a June 25, 2025 press release entitled “Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus.” The document reports that the clinical-stage TechBio company is adding a Group A Strep prophylactic candidate to its AI-Immunology-powered vaccine portfolio.
The submission is informational only: it contains no financial statements, guidance, capital-raising details, or clinical timelines. The press release (Exhibit 99.1) is incorporated by reference into multiple outstanding registration statements (Forms S-8, F-1 and F-3), ensuring that future prospectuses automatically reflect the new program.
There are no disclosures of changes in management, litigation, risk factors, or business strategy beyond the stated pipeline expansion. Accordingly, the filing signals strategic breadth but offers limited quantifiable data for investors to model near-term cash requirements or milestones.